<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487226</url>
  </required_header>
  <id_info>
    <org_study_id>KGOG1012</org_study_id>
    <nct_id>NCT01487226</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer</brief_title>
  <official_title>A Phase II Trial of Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in FIGO Stage IA2-IIA Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose Primary endpoint

        -  To evaluate the 3-year disease free survival Second endpoints

        -  To evaluate the 3-year &amp; 5-year overall survival To analyze the toxicity and the quality
           of life
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>log-rank test Cox regression analysis</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks * 6 cycles</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 50mg/m2</intervention_name>
    <description>Cisplatin 50mg/m2
Repeat every 3 weeks * 6 cycles</description>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cervical cancer stage Ia2-IIa

          -  histology; squamous, adeno, adenosquamous subtype

          -  age; 20∼70 years

          -  performance status; GOG 0∼2

          -  no medical illness

          -  hematologic, renal, hepatic function; normal

          -  grossly no residual disease

          -  histologically confirmed lymph nodes metastases

          -  no parametrial extension and negative resection margin

          -  number of retrieved lymph nodes; ≥ 20

        Exclusion Criteria:

          -  patients with grade 2 peripheral neuropathy

          -  patients with uncontrolled infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung-Hee University East-West Med. Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunkyung Park</last_name>
    <phone>8225125420</phone>
    <email>koreagynonco@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KGOG</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunkyung Park</last_name>
      <phone>8225125420</phone>
      <email>koreagynonco@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>December 6, 2011</last_update_submitted>
  <last_update_submitted_qc>December 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean Gynecologic Oncology Group</investigator_affiliation>
    <investigator_full_name>Taek Sang Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

